Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP

Efficacy and Safety of treatment with biologicals for severe Chronic Rhinosinusitis with Nasal Polyps A systematic review for the EAACI Guidelines

(2021) Ioana Agache et al.   ALLERGY

Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps

(2021) Anju T. Peters et al.   Journal of Allergy and Clinical Immunology-In Practice

Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma

(2021) Katrien Eger et al.   Journal of Allergy and Clinical Immunology-In Practice

Dupilumab rapidly improves asthma control in predominantly anti‐IL5/IL5R pretreated Austrian real‐life severe asthmatics

(2021) Andreas Renner et al.   Immunity Inflammation and Disease

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials

(2020) Philippe Gevaert et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy

(2020) Carlo Mümmler et al.   Journal of Allergy and Clinical Immunology-In Practice

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

(2019) Claus Bachert et al.   LANCET